

GEFTIFOS

For the use of Oncologist or a Hospital or a Laboratory only

Abbreviated Prescribing information for GEFTIFOS 250 (Gefitinib Tablets I.P.)

[Please refer the complete prescribing information for details]

PHARMACOLOGICAL PROPERTIES: (Antineoplastic). Inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors.

INDICATIONS: For the treatment of non small cell lung cancer in adult patients.

DOSAGE AND ADMINISTRATION: One 250 mg tablet once a day.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients, Breast-feeding.

WARNINGS AND PRECAUTIONS: Interstitial lung disease (ILD), Hepatotoxicity and liver impairment, Renal Impairment.

DRUG INTERACTIONS: CYP3A4 inducers: decrease gemcitabine plasma concentration Oral anticoagulants: increase in INR and increase in bleeding risk.

ADVERSE REACTIONS: Anorexia, Conjunctivitis, blepharitis, and dry eye, Haemorrhage, Interstitial lung disease, Neutrophils Granulocytes decreased, Leucocytes decreased Hemoglobin decreased, Platelets decreased, Dehydration, Neuropathy, Taste disturbances, Diarrhoea, Vomiting, Nausea, Constipation, Rash, Alopecia, Creatinine Clearance decreased, Fatigue, Bradycardia, Cardiomyopathy, asymptomatic ventricular tachycardia, Neurotoxicity.